Carcinoid syndrome historical perspective

Carcinoid syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Carcinoid Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Carcinoid syndrome historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Carcinoid syndrome historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Carcinoid syndrome historical perspective
CDC on Carcinoid syndrome historical perspective
Carcinoid syndrome historical perspective in the news
Blogs on Carcinoid syndrome historical perspective
Directions to Hospitals Treating Carcinoid syndrome
Risk calculators and risk factors for Carcinoid syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The term Carcinoid was given by Siegfried Oberndorfer, a German pathologist at the University of Munich in 1907. Enterochromaffin cell, the cell of origin of carcinoid tumour had been identified as early as 1897 by N. Kulchitsky.

Historical Perspective

• Theodor Langhans (1839–1915) was the first to describe the histology of a carcinoid tumor in 1867.
• The term Carcinoid was given by Siegfried Oberndorfer, a German pathologist at the University of Munich in 1907.
• Siegfried Oberndorfer referred the carcinoid tumor as "benign carcinomas" as they had distinct clinical entities and named them "karzinoide"(carcinoma-like).
• Karzinoide or “carcinoma-like” describes the unique feature of behaving like a benign tumor despite resembling a carcinoma microscopically.
• Rapport and colleagues isolated and named serotonin (5-HT), initially identified as a vasoconstrictor substance in the serum.
• Enterochromaffin cell,the cell of origin of carcinoid tumour had been identified as early as 1897 by N. Kulchitsky (1856-1925).
• In 1953, F. Lembeck established that enterochromaffin cells synthesizes and secretes serotonin, the major hormone responsible for carcinoid syndrome.